Bjoern C Froehlich

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Ejection Fraction

End Stage Renal Disease

Patient Reported Outcomes

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, René Peiman Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications 4 (8) (2024)
Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, René Peiman Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications 4 (8) (2024)
Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, René Peiman Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist
mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours. Cancer research communications (2024)
Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, René Peiman Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist
mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications 4 (8) (2024)